Chronic Iron Overload
Conditions
Keywords
Physician Survey,, PAS,, Deferasirox
Brief summary
The objective of this survey is to assess the knowledge of HCPs in relation to the recommended posology and biological monitoring for Exjade, based on the current locally valid Exjade educational materials (including the physician's reference checklist)
Interventions
OTHERPhysician survey
Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Physicians will be required to meet all of the following inclusion criteria: * Must provide consent for participation * Must spend ≥50% of time in direct patient care * Have treated patients with transfusional iron overload or non-transfusion-dependent thalassemia with chelation therapy during the last 12 months. * Have prescribed Exjade and/or generic deferasirox within the last 12 months.
Exclusion criteria
Physicians meeting the following criterion will not be eligible to take the survey: • Currently employed by a pharmaceutical company, health care company, market research company, advertising agency, or government agency involved in pharmaceutical research or marketing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean percentage of correct responses related to knowledge of posology and biological monitoring recommendations as described in the Exjade EU Summary of Product Characteristics (SmPC) | Through study completion, an average of 6 months. | The primary endpoint is a composite endpoint based on the percentages of HCPs with correct responses to all questions included in the composite regarding the below information: * Administration and dosing of Exjade (deferasirox) FCT * Biological monitoring |
Countries
Switzerland
Outcome results
None listed